# Everolimus and OSI-906 for Patients With Refractory Metastatic Colorectal Cancer

> **NCT01154335** · PHASE1 · COMPLETED · sponsor: **SCRI Development Innovations, LLC** · enrollment: 18 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** OSI-906
- **DRUG:** Everolimus

## Key facts

- **NCT ID:** NCT01154335
- **Lead sponsor:** SCRI Development Innovations, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07
- **Primary completion:** 2013-05
- **Final completion:** 2013-05
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2022-05-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01154335

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01154335, "Everolimus and OSI-906 for Patients With Refractory Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01154335. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*